CD40LG and infection: The frequency of HEV infection differed between recipients of solvent/detergent–treated plasma lots A and B. Although all (13/13, 100%) evaluable recipients of lot A solvent/detergent–treated plasma had been in contact with HEV (posttransfusion positive for HEV RNA or HEV IgG or IgM for all recipients), this finding was not observed for recipients of lot B, for which only 3 evaluable recipients had HEV antibody markers of infection (3/17, 18%) (p<0.001 by χ2 test).